COR logo

Cencora Inc. (COR)

$324.35

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on COR

Market cap

$61.89B

EPS

13.47

P/E ratio

24

Price to sales

0.19

Dividend yield

0.74%

Beta

0.582117

Price on COR

Previous close

$325.37

Today's open

$321.82

Day's range

$320.06 - $327.43

52 week range

$244.82 - $377.54

Profile about COR

CEO

Robert P. Mauch

Employees

51000

Headquarters

Conshohocken, PA

Exchange

New York Stock Exchange

Shares outstanding

190827165

Issue type

Common Stock

COR industries and sectors

Healthcare

Medical Distributors

News on COR

Cencora (COR) Reports Next Week: Wall Street Expects Earnings Growth

Cencora (COR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

news source

Zacks Investment Research • Oct 28, 2026

news preview

Cencora to Acquire AON in $2.4B Deal to Expand Oncology Network

COR's $2.4B acquisition of AON aims to expand its oncology services platform, strengthen community cancer care and support long-term growth.

news source

Zacks Investment Research • Oct 28, 2026

news preview

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Surgery Partners, Inc. (Nasdaq – SGRY), Range Resources Corporation (NYSE – RRC), American Oncology Network, Inc. (OTCQX – AONC), Utz Brands, Inc. (NYSE – UTZ)

BALA CYNWYD, Pa., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.

news source

GlobeNewsWire • Oct 26, 2026

news preview

Cencora to acquire American Oncology Network in $2.4 billion deal

Drug distributor Cencora said on Wednesday it would acquire American Oncology Network in a deal valuing ​the cancer care provider at up to $2.4 billion, deepening its ‌reach in community oncology across the United States.

news source

Reuters • Oct 21, 2026

news preview

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Passage Bio, Inc. (Nasdaq – PASG), American Oncology Network, Inc. (OTCQX – AONC), Utz Brands, Inc. (NYSE – UTZ), Finward Bancorp (Nasdaq – FNWD)

BALA CYNWYD, Pa., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.

news source

GlobeNewsWire • Oct 21, 2026

news preview

Cencora to Acquire American Oncology Network to Strengthen Support of Community Oncology

CONSHOHOCKEN, Pa. & FORT MYERS, Fla.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced it has signed a definitive agreement to acquire American Oncology Network, Inc. (“AON”) (OTCQX: AONC), a physician-led network of more than 350 oncology providers across 21 states. “The acquisition of AON will expand our physician-led oncology MSO and support of care in communities across the country,” said Robert P. Mauch, President and Chief Executive Officer of Cencora. “AON serves as a trusted p.

news source

Business Wire • Oct 21, 2026

news preview

AI Disruption May Benefit Cencora More Than Hims & Hers

Cencora (COR) stands to benefit from AI-driven increases in prescription volumes as regulatory pilots expand automated prescribing. COR's operational leverage and AI-enabled efficiency improvements have driven adjusted operating income up 17% YoY, outpacing 4.9% sales growth. Trading at a forward GAAP P/E of 17.7x—about 25% below sector median—COR merits a 12.5% re-rating, targeting $365–$366 per share.

news source

Seeking Alpha • Oct 14, 2026

news preview

Cencora Remains A Buy At These Prices, As Healthcare Supply-Chain Needs Grow

Cencora gets its prior buy rating reaffirmed again. Despite some market underperformance, specific business and macro fundamentals remain supportive. An investment-grade rating, positive operating cash flow, dividend safety, and an improved operating margin underscore the thesis.

news source

Seeking Alpha • Oct 6, 2026

news preview

Cencora Announces Date and Time for Fourth Quarter Fiscal 2026 Earnings Release

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced that it plans to release its results for the Fourth Quarter of Fiscal 2026 on Wednesday, November 4, 2026, prior to the opening of trading on the New York Stock Exchange. The Company will host a conference call to discuss the results at 8:30 a.m. ET on November 4, 2026.Participating in the conference call will be:Robert P. Mauch, President & Chief Executive OfficerEva C. Boratto, Executive Vice President & Chie.

news source

Business Wire • Oct 2, 2026

news preview

Cencora Elects Robert E. Sanchez to Its Board of Directors

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced that its Board of Directors has elected Robert E. Sanchez as a new independent director, effective October 1, 2026. Mr. Sanchez is the Executive Chair of Ryder System, Inc., where he previously served as Chair and Chief Executive Officer until his retirement in March 2026. Prior to being appointed CEO in 2013, Mr. Sanchez spent two decades with Ryder serving in roles of increasing responsibility including President an.

news source

Business Wire • Sep 25, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Cencora Inc.

Open an M1 investment account to buy and sell Cencora Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in COR on M1